Clinical trials: Cognitive Function Decline
Alzheimer Disease, Mini-Mental State Examination
Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients
This study looks at people with Alzheimer's disease to find out which factors are linked to their initial score on the Mini-Mental State Examination (MMSE) and which factors may predict a fast decline in their score over 12…
- Conditions
- Alzheimer Disease, Mini-Mental State Examination, Cognitive Dysfunction, Neuropsychological Tests
- Trial name
- NCT07122856
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier de Gonesse
Movement Disorder, Cognitive Decline
Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases
In the study, NextGen SE are on-hand a cohort comprising each 50 pediatric and 50 adult patients, and in which there are an unclear movement disorder or an unclear cognitive disorder, examines the following questions : Primary…
- Trial name
- NextGen-SE (NCT02588638)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Tuebingen
Alzheimer's Disease
Development and Decline of Brain and Cognition Through the Life Span
The protocol objectives are to enable prospective IRB review of research using human MRI scans and data collected under other branch protocols or extramural sources.
- Trial name
- NCT00880451
- Where
- United States
- Sponsor
- National Institute of Mental Health (NIMH)
Tuberous Sclerosis Complex, Aspirin
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
There had been much evidence in aspirin controlling tumorous conditions conducted by basic researches, especially through mammilian target of rapamycin (mTOR) pathway.
- Conditions
- Tuberous Sclerosis Complex, Aspirin, Epilepsy, Cognitive Decline
- Trial name
- NCT03356769
- Testing
- Aspirin, AED
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
Upper Extremity Dysfunction, Dementia
Upper Limb Reeducation Across Life Span
Program Ready2E.A.T. was developed to be tested in the upper limb reeducation on population at risk, such as: Children with dysfunction Cognitive impaired elderly Dementia people
- Conditions
- Upper Extremity Dysfunction, Dementia, Cerebral Palsy, Cognitive Decline
- Trial name
- ULReed (NCT03997591)
- Testing
- Ready2E.A.T. PROGRAM
- Where
- Portugal
- Volunteers
- 15 people
- Sponsor
- Instituto Politécnico de Leiria